Dose appears to matter: the effect on drinking in the Lancet trial appeared at the full 2.4 mg dose, while the lower-dose JAMA Psychiatry trial found weaker real-world effects
"In the context of a reduced appetite, large weight losses, and a significant loss in muscle, it is important to help people focus on dietary protein and activity to minimize the loss of muscle mass."
Furthermore, co-treatment with a GLP-1R agonist and a GIPR agonist results in more insulin sensitivity, glucose reduction, food intake reduction, and body weight reduction than either agonist alone in obese mice with type 2 diabetes (33)
Patients who experience gastrointestinal side effects like nausea or vomiting on one medication may sometimes tolerate the other better
Yet, the GLP-1 trend is merely a reflection
A muscle-preserving weight-loss strategy may include: Medical history review Weight and body-composition goals Nutrition planning Protein guidance Resistance-training recommendations Metabolic lab review Hormone and thyroid considerations when appropriate Medication review GLP-1 education Peptide therapy discussion when medically appropriate Ongoing monitoring and adjustment This type of care is especially important for patients who have: Insulin resistance Prediabetes Type 2 diabetes Menopause-related body-composition changes Low energy Low muscle mass A history of repeated dieting Thyroid concerns High stress Poor sleep Prior weight regain Concerns about rapid weight loss For these patients, a generic weight-loss plan is rarely enough
